Published in Handb Exp Pharmacol on January 01, 2011
AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest (2013) 2.44
Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis (2012) 1.52
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun (2012) 1.41
Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging (Albany NY) (2011) 1.01
Metformin-stimulated AMPK-α1 promotes microvascular repair in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2013) 0.89
Phytochemistry and biological properties of glabridin. Fitoterapia (2013) 0.86
AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome. Antioxid Redox Signal (2015) 0.85
Activation of AMP-activated protein kinase in cerebella of Atm-/- mice is attributable to accumulation of reactive oxygen species. Biochem Biophys Res Commun (2012) 0.85
Adiponectin signaling in the liver. Rev Endocr Metab Disord (2014) 0.84
Modulation of de novo purine biosynthesis leads to activation of AMPK and results in improved glucose handling and insulin sensitivity. J Diabetes Metab Disord (2014) 0.80
AMP-activated protein kinase as regulator of P2Y(6) receptor-induced insulin secretion in mouse pancreatic β-cells. Biochem Pharmacol (2013) 0.79
Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget (2016) 0.79
Pre-germinated brown rice prevents high-fat diet induced hyperglycemia through elevated insulin secretion and glucose metabolism pathway in C57BL/6J strain mice. J Clin Biochem Nutr (2014) 0.78
AMPK couples plasma renin to cellular metabolism by phosphorylation of ACC1. Am J Physiol Renal Physiol (2013) 0.78
Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. J Pediatr Endocrinol Metab (2014) 0.76
Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell Discov (2017) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 23.95
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Resveratrol improves health and survival of mice on a high-calorie diet. Nature (2006) 20.91
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation (1986) 19.82
The metabolic syndrome. Lancet (2005) 19.47
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell (2006) 19.16
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature (2003) 17.52
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 16.62
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med (2001) 16.51
Insulin signalling and the regulation of glucose and lipid metabolism. Nature (2001) 16.41
Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature (2006) 15.48
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 14.15
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science (2003) 11.39
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature (2009) 10.59
Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature (2004) 10.32
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature (2007) 10.21
Mechanisms linking obesity with cardiovascular disease. Nature (2006) 9.07
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes (1995) 8.95
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature (2002) 8.77
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A (2007) 8.23
AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature (2004) 7.64
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature (2005) 7.14
5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem (1995) 7.12
Guidelines for healthy weight. N Engl J Med (1999) 7.03
AMPK and PPARdelta agonists are exercise mimetics. Cell (2008) 6.39
AMPK in Health and Disease. Physiol Rev (2009) 6.38
The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem (2002) 6.36
Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med (2005) 6.04
AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A (2002) 5.93
AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol (1997) 5.74
Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol (2005) 5.54
SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem (2010) 5.43
Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab (2005) 5.39
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 5.18
Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13
SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab (2008) 4.89
Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci U S A (2007) 4.87
Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation (2001) 4.82
Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem (2002) 4.79
SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab (2007) 4.75
Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab (2006) 4.64
AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol (1999) 4.58
AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest (2004) 4.54
Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J (2007) 4.48
Type 2 diabetes-a matter of beta-cell life and death? Science (2005) 4.46
Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A (2002) 4.40
Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes (1995) 4.33
Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem (2005) 4.32
Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes (1998) 4.31
Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A (2007) 4.24
Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem (2002) 4.16
SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem (2008) 4.16
Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med (2004) 4.05
Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A (2001) 3.96
Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes (2006) 3.85
AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem (2004) 3.84
SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem (2008) 3.66
AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett (1999) 3.63
Regulation of fasted blood glucose by resistin. Science (2004) 3.54
Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab (2010) 3.46
Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab (2001) 3.45
AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes (2009) 3.39
Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol (1985) (2000) 3.37
Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol (2008) 3.32
Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem (2006) 3.31
Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol (2000) 3.27
Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol (1985) (1999) 3.14
Acute stimulation of glucose metabolism in mice by leptin treatment. Nature (1997) 3.12
AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci (2005) 3.04
Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care (2009) 3.03
Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem (2004) 3.01
Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes (2005) 2.88
Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care (2006) 2.86
Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes (2006) 2.80
Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med (2004) 2.80
Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology (2003) 2.76
5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes (1999) 2.73
Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett (1994) 2.65
Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr (2006) 2.57
Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care (2001) 2.50
Mechanisms of beta-cell death in type 2 diabetes. Diabetes (2005) 2.50
AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J (1999) 2.46
Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab (2006) 2.43
5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes (2000) 2.39
AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res (2009) 2.38
AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem (1998) 2.38
Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem (1998) 2.25
Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J (2005) 2.17
Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes (2002) 2.15
Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J Biol Chem (2006) 2.13
Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem (2002) 2.11
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest (2010) 5.39
The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest (2003) 4.11
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem (2003) 3.58
Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes (2005) 2.88
Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab (2008) 2.60
Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol (2006) 2.47
Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J (2005) 2.17
AMPK: Lessons from transgenic and knockout animals. Front Biosci (Landmark Ed) (2009) 2.09
AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol (2010) 1.93
The alpha2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes (2004) 1.75
Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci (Landmark Ed) (2009) 1.51
AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Biochem J (2007) 1.30
Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes (2011) 1.19
Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states. J Clin Endocrinol Metab (2003) 1.03
Essential role of chicken ovalbumin upstream promoter-transcription factor II in insulin secretion and insulin sensitivity revealed by conditional gene knockout. Diabetes (2005) 0.95
Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol Metab (2013) 0.90
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases]. Med Sci (Paris) (2006) 0.87
Intestinal gluconeogenesis: key signal of central control of energy and glucose homeostasis. Curr Opin Clin Nutr Metab Care (2009) 0.83
Effect of venous drainage site on insulin action after simultaneous pancreas-kidney transplantation. Transplantation (2004) 0.80
Maintenance of red blood cell integrity by AMP-activated protein kinase alpha1 catalytic subunit. FEBS Lett (2010) 0.79
[Physiological roles of AMP-activated protein kinase (AMPK)]. Med Sci (Paris) (2003) 0.76
Differential pre-mRNA splicing regulates Nnat isoforms in the hypothalamus after gastric bypass surgery in mice. PLoS One (2013) 0.75
Expression and regulation by insulin of low-density lipoprotein receptor-related protein mRNA in human skeletal muscle. Biochim Biophys Acta (2002) 0.75
[Role of intestinal flora in insulin resistance and obesity]. Presse Med (2008) 0.75
[Treatment of type 2 diabetes by metformin]. Rev Prat (2015) 0.75